2seventy bio, Inc. (NASDAQ: TSVT) reported Q4 EPS of ($1.11), $0.08 worse than the analyst estimate of ($1.03). Revenue for the quarter came in at $10.68 million versus the consensus estimate of $14.78 million.

For earnings history and earnings-related data on 2seventy bio, Inc. (TSVT) click here.